Jeremy Grantham Novo Nordisk A S Transaction History

Grantham, Mayo, Van Otterloo & Co. LLC

$31.8 Billion
Q2 2025

A detailed history of Jeremy Grantham (Grantham, Mayo, Van Otterloo & Co. LLC) transactions in Novo Nordisk A S stock. As of the latest transaction made, Grantham, Mayo, Van Otterloo & Co. LLC holds 61,585 shares of NVO stock, worth $3.26 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

61,585

Previous 37,617 63.72%

Holding current value

$3.26 Million

Previous $2.61 Million 62.71%

% of portfolio

0.01%

Previous 0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$58.08 - $81.05 $1.39 Million - $1.94 Million	23,968 Added 63.72%	61,585 $4.25 Million
Q1 2025 May 14, 2025	BUY	$69.3 - $90.95 $2.61 Million - $3.42 Million	37,617 New	37,617 $2.61 Million
Q3 2019 Nov 13, 2019	SELL	$47.54 - $53.43 $34.9 Million - $39.2 Million	-733,180 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$46.79 - $52.47 $20.8 Million - $23.3 Million	-443,600 Reduced 37.7%	733,180 $37.4 Million
Q1 2019 May 14, 2019	BUY	$46.36 - $52.63 $8.15 Million - $9.25 Million	175,800 Added 17.56%	1,176,780 $61.6 Million
Q4 2018 Feb 13, 2019	BUY	$41.54 - $47.25 $710,334 - $807,975	17,100 Added 1.74%	1,000,980 $46.1 Million
Q3 2018 Nov 14, 2018	BUY	$46.76 - $51.24 $14.1 Million - $15.5 Million	302,353 Added 44.36%	983,880 $46.4 Million
Q2 2018 Aug 14, 2018	BUY	$44.29 - $50.42 $1.09 Million - $1.24 Million	24,527 Added 3.73%	681,527 $31.4 Million
Q1 2018 May 15, 2018	BUY	$48.49 - $58.14 $31.9 Million - $38.2 Million	657,000 New	657,000 $32.4 Million

Others Institutions Holding NVO

# of Institutions

1,708

Shares Held

312M

Call Options Held

13.7M

Put Options Held

19.7M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $119B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track Jeremy Grantham's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Grantham, Mayo, Van Otterloo & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grantham, Mayo, Van Otterloo & Co. LLC and Jeremy Grantham with notifications on news.

Account